Drug Controller General of India
-
DCGI approves MSD India’s drug KEYTRUDA for triple-negative breast cancer, renal cell carcinoma
KEYTRUDA is an immunotherapy that works with the immune system to help fight cancer cells KEYTRUDA is now approved for…
Read More » -
Glenmark Specialty bags DCGI approval for Phase 1 trial novel molecule GRC 54276
Glenmark will initiate a Phase 1 clinical trial by June 2022 to determine the safety, tolerability, and preliminary anti-tumour activity…
Read More » -
PNB Vesper completes Phase 2 clinical trials of GPP-Baladol on COVID-19 patients
The clinical trial report will be submitted to Drug Controller General of India on February 22, 2021 Kerala-based PNB Vesper…
Read More » -
AstraZeneca Pharma gets DCGI nod to market asthma drug
AstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India AstraZeneca Pharma…
Read More » -
Mylan’s Remdesivir Injection Gets DCGI Approval for Restricted Emergency Use in COVID-19
Hertfordshire, Uk, Pittsburgh, U.S. and Bengaluru, India: Mylan N.V. the pharma MNC said that its remdesivir 100 mg/vial got Drug…
Read More »